GGrantIndex
Sort

48,018 grants matching immunotherapy

Combining AD Epitope Vaccine with Innate Immunity

$433,515
David Hastings Cribbs · University Of California-Irvine · R01 · FY2012 · NS

Role of CHI3L1 in accelerating breast cancer metastasis: a mechanistic approach

$433,500
Vijaya L Iragavarapu-Charyulu · Florida Atlantic University · R15 · FY2012 · CA

Modulation of Mcl-1 for Treatment of Lung Cancer

$433,488
Xingming Deng · Emory University · R01 · FY2021 · CA

Study of Interleukin 33 as a new immunotherapy of lung cancer

$433,485
Binfeng Lu · Hackensack University Medical Center · R01 · FY2023 · CA

Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface

$433,439
Melody A Swartz · University Of Chicago · R01 · FY2021 · CA

Mechanistic studies of anti-tau antibodies effects on tau biochemistry

$433,433
Colin G Wu · Oakland University · R15 · FY2016 · GM

Protecting Pancreatic Islet Grafts from Rejection

$433,415
Isogenis, Inc. · R43 · FY2004 · DK

Chemotherapy plus vaccine for metastatic breast cancer

$433,408
Johns Hopkins University · R01 · FY2003 · CA

Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma

$433,378
Marc Ladanyi · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA

Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs

$433,366
Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2023 · CA

MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY

$433,354
University Of Washington · R37 · FY2000 · CA

Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach

$433,304
Maurizio Pellecchia · University Of California Riverside · R01 · FY2020 · CA

Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach

$433,304
Maurizio Pellecchia · University Of California Riverside · R01 · FY2021 · CA

Lung Cancer Vaccine

$433,293
Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2024 · CA

INHIBITION OF NEUROPILIN-2 TO ENHANCE IMMUNOTHERAPY OF LETHAL PROSTATE CANCER

$433,258
University Of Massachusetts Medical School · · FY2021 · Defense Health Agency

Targeting a PHGDH metabolic vulnerability in melanoma

$433,256
Florian Karreth · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2024 · CA

A Wireless Multi-function Microscope for Lifetime Imaging of the Brain Tumor Vasculome

$433,229
Arvind P Pathak · Johns Hopkins University · R01 · FY2021 · CA

Development of mosaic enterovirus mRNA vaccine to prevent hand, foot and mouth disease

$433,175
Todd Christopher Bradley · Children'S Mercy Hosp (Kansas City, Mo) · R21 · FY2025 · AI

Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors

$433,173
Ashish Ranjan · Oklahoma State University Stillwater · R01 · FY2022 · CA

Functional Analysis of MicroRNAs and Target Genes in Immune Tolerance

$433,154
Changchun Xiao · Scripps Research Institute, The · R01 · FY2019 · AI

Heterlogous Prime and Boost Vaccine Strategies

$433,149
Duke University · P01 · FY2005 · CA

Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy

$433,138
Wei Wei · Institute For Systems Biology · R33 · FY2022 · CA

Peripheral Adaptive Immune System Changes Associated with Alzhiemer's Disease

$433,126
Naresha Saligrama · Washington University · R21 · FY2021 · AG

Post-transplant vaccines to enhance graft-versus-leukemia responses

$433,125
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2012 · HL

Inhibiting Corneal Neovascularization by Targeting Tissue Factor

$433,125
Hua Zhu · Ohio State University · R21 · FY2025 · EY